The first paper described the general dynamics of a CD8 + T cell response to vaccination with a recombinant human adenovirus serotype 5 (rHuAd5) vector that can be used as a general delivery vehicle to express human tumor antigens [16]. This evidence concerns the gene CD8A and neoplasm.